Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

NYSE:AMRX  
4.93
0.00 (0.00%)
Products

Amneal Announces U.S. FDA Filing Acceptance Of Biologics License Application (BLA) For Bevacizumab

Published: 06/17/2021 12:15 GMT
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A (AMRX) - Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (bla) for Bevacizumab.
Amneal Pharmaceuticals - FDA Accepted for Review Bla for Bevacizumab, With Standard Review Goal Date in Q2 2022 According to Biosimilar User Fee Act.